We are live on ! Find out more
SLRN

ACELYRIN
SLRN

Delisted

SLRN was delisted on the 21st of May, 2025.

Back to rankings

82 hedge funds and large institutions have $1.6B invested in ACELYRIN in 2023 Q2 according to their latest regulatory filings, with 82 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3,526% more call options, than puts

Call options by funds: $2.79M | Put options by funds: $77K

79.39% more ownership

Funds ownership: 0% → 79.39% (+79%)

Holders
82
Holders Change
+82
Holders Change %
–
% of All Funds
1.28%
Holding in Top 10
8
Holding in Top 10 Change
+8
Holding in Top 10 Change %
% of All Funds
0.13%
New
82
Increased
–
Reduced
–
Closed
–
Calls
$2.79M
Puts
$77K
Net Calls
+$2.71M
Net Calls Change
+$2.71M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$152M
2
Citadel Advisors
Citadel Advisors
Florida
+$124M
3
O
OrbiMed
New York
+$109M
4
OM
Opaleye Management
Massachusetts
+$85.1M
5
VP
venBio Partners
California
+$78.9M

Top Sellers

No sellers this quarter

SLRN Hedge Fund Activity: Q2 2023 in Review

82 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q2 2023, worth a combined $1.6B.

Buyers outnumbered sellers: 82 funds opened new SLRN positions and 0 closed out — a net gain of 82 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $152M.

  • 82 institutional investors held ACELYRIN (SLRN) as of Q2 2023, up from 0 in Q1 2023.
  • Funds reported $1.6B of ACELYRIN stock for Q2 2023.
  • 82 funds opened new ACELYRIN positions in Q2 2023 and 0 closed out, a net change of +82 holders.
  • The largest ACELYRIN buyer in Q2 2023 was Fidelity Investments, an estimated $152M added.

Based on aggregated 13F filings for Q2 2023.